cA2 CenTNF anti-TNF antibody data

CNTO reported additonal data from two previously released trials of cA2 in the inflammatory bowel disorder at Digestive Disease Week in Washington.

Results of an extension of trial T16 showed a prolonged benefit of cA2

Read the full 354 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE